Ozempic, the blockbuster weight-loss drug, has ignited a ferocious debate over the ethics and efficacy of treating obesity with medication. Oddly, this intense ideological battle has glossed over perhaps the most important question we should answer: How does the drug impact individual patients? Dr. Chuck Dinerstein, ACSH’s Director of Medicine, is working to correct that oversight by documenting his own experience with Ozempic.
Join Cameron English and Dr. Chuck Dinerstein on Episode 83 of the Science Dispatch podcast as they discuss:
Let’s dive into the rollercoaster of expectations, disappointments, and the occasional triumph as I document every twist and turn in my journey with the much-hyped Ozempic that promises to whip my cardiovascular risks into shape while conveniently shedding a few pounds.
Listen to the Science Dispatch on iTunes Spotify, Stitcher and Google Podcasts. Or add the RSS feed to your favorite podcast app. Join our Dispatch newsletter to get these stories and more delivered to your inbox.